Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:49 UTC |
---|
Update Date | 2022-03-07 02:51:40 UTC |
---|
HMDB ID | HMDB0014584 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Gemcitabine |
---|
Description | Gemcitabine is a nucleoside analog used as chemotherapy. It is marketed as Gemzar by Eli Lilly and Company. As with fluorouracil and other analogues of pyrimidines, the drug replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumor growth, as new nucleosides cannot be attached to the 'faulty' nucleoside, resulting in apoptosis (cellular 'suicide'). |
---|
Structure | NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 |
---|
Synonyms | Value | Source |
---|
2',2'-Difluorodeoxycytidine | ChEBI | 2'-Deoxy-2',2'-difluorocytidine | ChEBI | 4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one | ChEBI | Gemcitabina | ChEBI | Gemcitabinum | ChEBI | DFdCyd | HMDB | 2',2'-Difluoro-2'-deoxycytidine | HMDB | 2'-Deoxy-2'-difluorocytidine | HMDB | Gemcitabine, (D-threo-pentafuranosyl)-isomer | HMDB | Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer | HMDB | 2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate | HMDB | Gemcitabine hydrochloride | HMDB | 2',2'-DFDC | HMDB | Gemzar | HMDB | Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer | HMDB |
|
---|
Chemical Formula | C9H11F2N3O4 |
---|
Average Molecular Weight | 263.1981 |
---|
Monoisotopic Molecular Weight | 263.071762265 |
---|
IUPAC Name | 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydropyrimidin-2-one |
---|
Traditional Name | gemcitabine |
---|
CAS Registry Number | 95058-81-4 |
---|
SMILES | NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F |
---|
InChI Identifier | InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 |
---|
InChI Key | SDUQYLNIPVEERB-QPPQHZFASA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. Pyrimidine 2'-deoxyribonucleosides are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2. |
---|
Kingdom | Organic compounds |
---|
Super Class | Nucleosides, nucleotides, and analogues |
---|
Class | Pyrimidine nucleosides |
---|
Sub Class | Pyrimidine 2'-deoxyribonucleosides |
---|
Direct Parent | Pyrimidine 2'-deoxyribonucleosides |
---|
Alternative Parents | |
---|
Substituents | - Pyrimidine 2'-deoxyribonucleoside
- Aminopyrimidine
- Pyrimidone
- Hydropyrimidine
- Pyrimidine
- Imidolactam
- Heteroaromatic compound
- Tetrahydrofuran
- Fluorohydrin
- Halohydrin
- Secondary alcohol
- Organoheterocyclic compound
- Azacycle
- Oxacycle
- Alkyl halide
- Organopnictogen compound
- Primary amine
- Primary alcohol
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Organic oxygen compound
- Alkyl fluoride
- Alcohol
- Organic nitrogen compound
- Amine
- Organic oxide
- Hydrocarbon derivative
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 168.64 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 22.3 g/L | Not Available | LogP | -1.4 | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Gemcitabine,1TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O | 2133.3 | Semi standard non polar | 33892256 | Gemcitabine,1TMS,isomer #2 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N)=NC2=O)C1(F)F | 2157.9 | Semi standard non polar | 33892256 | Gemcitabine,1TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1 | 2231.3 | Semi standard non polar | 33892256 | Gemcitabine,2TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C | 2132.7 | Semi standard non polar | 33892256 | Gemcitabine,2TMS,isomer #2 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O)C2(F)F)C=C1 | 2200.7 | Semi standard non polar | 33892256 | Gemcitabine,2TMS,isomer #3 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C)C2(F)F)C=C1 | 2211.2 | Semi standard non polar | 33892256 | Gemcitabine,2TMS,isomer #4 | C[Si](C)(C)N(C1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1)[Si](C)(C)C | 2178.7 | Semi standard non polar | 33892256 | Gemcitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)C2(F)F)C=C1 | 2229.2 | Semi standard non polar | 33892256 | Gemcitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)C2(F)F)C=C1 | 2261.3 | Standard non polar | 33892256 | Gemcitabine,3TMS,isomer #1 | C[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C)[C@@H](O[Si](C)(C)C)C2(F)F)C=C1 | 2509.1 | Standard polar | 33892256 | Gemcitabine,3TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2195.7 | Semi standard non polar | 33892256 | Gemcitabine,3TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2314.7 | Standard non polar | 33892256 | Gemcitabine,3TMS,isomer #2 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2486.2 | Standard polar | 33892256 | Gemcitabine,3TMS,isomer #3 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C1(F)F | 2181.0 | Semi standard non polar | 33892256 | Gemcitabine,3TMS,isomer #3 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C1(F)F | 2300.3 | Standard non polar | 33892256 | Gemcitabine,3TMS,isomer #3 | C[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C1(F)F | 2373.9 | Standard polar | 33892256 | Gemcitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C | 2239.1 | Semi standard non polar | 33892256 | Gemcitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C | 2323.3 | Standard non polar | 33892256 | Gemcitabine,4TMS,isomer #1 | C[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C)[Si](C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C | 2267.0 | Standard polar | 33892256 | Gemcitabine,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O | 2349.0 | Semi standard non polar | 33892256 | Gemcitabine,1TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N)=NC2=O)C1(F)F | 2362.9 | Semi standard non polar | 33892256 | Gemcitabine,1TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1 | 2471.3 | Semi standard non polar | 33892256 | Gemcitabine,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C(C)(C)C | 2577.4 | Semi standard non polar | 33892256 | Gemcitabine,2TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O)C2(F)F)C=C1 | 2650.7 | Semi standard non polar | 33892256 | Gemcitabine,2TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C2(F)F)C=C1 | 2635.5 | Semi standard non polar | 33892256 | Gemcitabine,2TBDMS,isomer #4 | CC(C)(C)[Si](C)(C)N(C1=NC(=O)N([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)C=C1)[Si](C)(C)C(C)(C)C | 2620.5 | Semi standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)C2(F)F)C=C1 | 2845.2 | Semi standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)C2(F)F)C=C1 | 2838.0 | Standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC(=O)N([C@@H]2O[C@H](CO[Si](C)(C)C(C)(C)C)[C@@H](O[Si](C)(C)C(C)(C)C)C2(F)F)C=C1 | 2813.9 | Standard polar | 33892256 | Gemcitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2795.3 | Semi standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2885.4 | Standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #2 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O | 2765.9 | Standard polar | 33892256 | Gemcitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C1(F)F | 2791.9 | Semi standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C1(F)F | 2872.1 | Standard non polar | 33892256 | Gemcitabine,3TBDMS,isomer #3 | CC(C)(C)[Si](C)(C)O[C@@H]1[C@@H](CO)O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C1(F)F | 2671.6 | Standard polar | 33892256 | Gemcitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C(C)(C)C | 3016.7 | Semi standard non polar | 33892256 | Gemcitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C(C)(C)C | 3067.1 | Standard non polar | 33892256 | Gemcitabine,4TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)OC[C@H]1O[C@@H](N2C=CC(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)=NC2=O)C(F)(F)[C@@H]1O[Si](C)(C)C(C)(C)C | 2679.9 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Gemcitabine GC-MS (Non-derivatized) - 70eV, Positive | splash10-00c3-9210000000-49e8caef8629bb5b3f0b | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Gemcitabine GC-MS (2 TMS) - 70eV, Positive | splash10-00or-7902000000-4e3542be1d6d35b1b0c4 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Gemcitabine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-03di-0930000000-e2122f1423d3060097b9 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-03di-0790000000-e66897c78fa010a45ab8 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0cfs-0910000000-e4e73c07b687772a1108 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0900000000-99f619802e3ba7bd8b2e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0900000000-18dd55d7372a11b9dfb7 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-1900000000-fdc016f6d17808e4cf1b | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-5900000000-ec478d4dfe03f80b91ad | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-03di-0790000000-0d953fc9632751f00f72 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-07xs-0920000000-0e8154089a57b6bef7c4 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0900000000-c54a530153a028d6ffcc | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0900000000-1f4cd6bc7d377fe7731e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0a4i-0900000000-c3cdcfa5d386ac7222fa | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-0aor-4900000000-337f45a27b7b12b1b2f0 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine LC-ESI-ITFT , negative-QTOF | splash10-03di-0920000000-52d24e07b71b7d08dcdb | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 90V, Negative-QTOF | splash10-0a4i-5900000000-ec478d4dfe03f80b91ad | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 75V, Negative-QTOF | splash10-0a4i-1900000000-fdc016f6d17808e4cf1b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 30V, Negative-QTOF | splash10-0cfs-0910000000-e4e73c07b687772a1108 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 15V, Negative-QTOF | splash10-03di-0790000000-e66897c78fa010a45ab8 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 45V, Negative-QTOF | splash10-0a4i-0900000000-99f619802e3ba7bd8b2e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 60V, Negative-QTOF | splash10-0a4i-0900000000-18dd55d7372a11b9dfb7 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 35V, Negative-QTOF | splash10-03di-0930000000-23c49f9312028218d2e1 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 30V, Negative-QTOF | splash10-07xs-0920000000-0e8154089a57b6bef7c4 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 60V, Negative-QTOF | splash10-0a4i-0900000000-1f4cd6bc7d377fe7731e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 75V, Negative-QTOF | splash10-0a4i-0900000000-c3cdcfa5d386ac7222fa | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Gemcitabine 45V, Negative-QTOF | splash10-0a4i-0900000000-c54a530153a028d6ffcc | 2021-09-20 | HMDB team, MONA | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-16 | Wishart Lab | View Spectrum |
|
---|